Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Ophthalmology Futures Retina Forum 2024
14 slides from Eyepoint's conference presentation, September 2024
Slide 1: EyePoint is Committed to Developing Therapeutics for Serious Retinal Disease
EyePoint is Committed to Developing Therapeutics to Help Improve the Lives of Patients with Serious Retinal Disease Ophthalmology Futures Retina Forum 2024 Ramiro Ribeiro, MD, PhD Chief Medical Officer DURAVYU has been conditionally accepted by the FDA as the proprietary name for DURAVYU. DURAVYU is
Slide 2: Legal Disclaimers
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even
Slide 3: Late-stage Clinical Company Pursuing Multi-Billion Dollar Markets
Late-stage Clinical Company Pursuing Multi-Billion Dollar Markets Phase 3 DURAVYU (vorolanib intravitreal insert) Asset Compelling Multi-billion-dollar market opportunities Pipeline Proven Technology Proprietary Durasert E drug delivery technology Strong Balance $280M of cash and investments on June
Slide 4: Pipeline Leveraging Innovative Drug Delivery Technology
Pipeline Leveraging Innovative Drug Delivery Technology Durasert E Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Next Milestone First Phase 3 Trial Wet AMD STATISTICALLY NON-INFERIOR TO SOC patient randomized DURAVYU (EYP-1901) – 2H 2024 vorolanib in Durasert E (tyrosine kinase inhi
Slide 5: DURAVYU (EYP-1901): Vorolanib in Durasert E
DURAVYUTM (EYP-1901): Vorolanib in Durasert ETM DURAVYU Vorolanib Durasert E Controlled release over a Potent receptor tyrosine kinase Bioerodible, sustained period of at least 6 months inhibitor (TKI): selectively inhibits all IVT drug delivery VEGF signaling No delay – reaches target tissues at th
Slide 6: DAVIO 2 Randomized, Double-Masked, Aflibercept Controlled Study Design
DAVIO 2 is Randomized, Double-Masked, Aflibercept Controlled* Study with a Single DURAVYU Treatment at Two Dose Levels -D14 to -D7 D1 W4 W8 W 12 W 16 W 20 W 24 W 28 W 32 W 36 to W56 DURAVYU 2mg low dose n=53 DURAVYU 3mg high dose n=54 Aflibercept 2mg q8W n=54 RA NDOMI Z AT IO N A FL IB ERCE PT q 8W
Slide 7: DURAVYU Statistically Non-Inferior in Change in BCVA Compared to Aflibercept
DURAVYU was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control (95% CI) M EAN CHA NG E I N B CVA F RO M BAS EL I NE 15 Mean Change in BCVA vs Aflibercept 10 DURAVYU 3mg Change in ETRDS letters DURAVYU 2mg -0.3* -0.4* 5 +1.3* +1.0* 0 +0.9* -5 -10 Aflibercept Aflibercept
Slide 8: Data from DAVIO Demonstrates Strong Anatomic Control Compared to Aflibercept
Data from DAVIO 2 Demonstrates Strong Anatomic Control of DURAVYU Compared to Aflibercept M EAN CHA NG E I N C ST 100 Mean Change in CST vs Aflibercept 75 DURAVYU 2mg DURAVYU 3mg CST Change, in microns 50 +12.4 +5.2 25 +17.8 um +10.6 um 0 +5.4 um -25 -50 -75 Aflibercept Aflibercept Aflibercept -100
Slide 9: DURAVYU 2mg Dose Reduced Treatment Burden by 89%
DURAVYU 2mg Dose Reduced Treatment Burden by 89% Compared to Prior 6 Months Injections in year prior and during the DAVIO 2 trial Anti-VEGF injection No injection Aflibercept loading dose Missed Visit Aflibercept + DURAVYU Supplemental injection DURAVYU 2 mg DURAVYU 3 mg (n = 50) (n = 52) 0% Change
Slide 10: DURAVYU 3mg Dose Reduced Treatment Burden by 85%
DURAVYU 3mg Dose Reduced Treatment Burden by 85% Compared to Prior 6 Months Injections in year prior and during DAVIO 2 trial Anti-VEGF injection No injection Aflibercept loading dose Missed Visit Aflibercept + DURAVYU Supplemental injection DURAVYU 2 mg DURAVYU 3 mg (n = 50) (n = 52) 0% Change in M
Slide 11: DURAVYU Positive Efficacy Outcomes and Excellent Safety Profile Across Indications
DURAVYU Demonstrated Positive Efficacy Outcomes and Excellent Safety Profile Across Multiple Indications DURAVYU HAS BEEN EVALUATED IN 191 PATIENTS TO DATE ACROSS DIFFERENT INDICATIONS Trial Indication Safety Key Efficacy Outcomes • Stable BCVA and OCT DAVIO wet AMD • 74% reduction in treatment burd
Slide 12: Phase 3 Trials Designed to Enable Global Regulatory Approval of DURAVYU
Phase 3 Trials are Designed to Enable Global Regulatory Approval of DURAVYU GLOBAL, RANDOMIZED, DOUBLE-MASKED, AFLIBERCEPT CONTROLLED OBJECTIVE DESIGN Demonstrate DURAVYU, when • Two pivotal, non-inferiority trials administered every six months, • ~400 patients per trial achieves similar visual outc
Slide 13: Clinical and Preclinical Data at Multiple Upcoming Scientific Conferences
Clinical and Preclinical Data will be Presented at Multiple Upcoming Scientific Conferences Medical Conference Data Timing DAVIO 2 sub-group analyses EURetina September 2024 Topline DAVIO 2 12-month data AAO DAVIO 2 12-month sub-group analyses October 2024 FloRetina DAVIO 2 encore presentation Decem
Slide 14: Thank You
Thank You DURAVYU has been conditionally accepted by the FDA as the proprietary name for DURAVYU. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. IVT, intravitreal injection
EyePoint Pharmaceuticals — Ophthalmology Futures Retina Forum 2024 on 6ix